News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CV Technologies Inc. (CC:CVQ) Release: Colds and Flu Cut by 1/3 in Four-City Trial of COLD-FX®



9/15/2008 2:44:49 PM

EDMONTON, ALBERTA--(Marketwire - Sept. 15, 2008) - CV Technologies Inc. (TSX:CVQ) today announced preliminary results of a clinical trial demonstrating that COLD-FX® significantly supplements the flu shot's effectiveness in seniors and cuts colds and flu by one-third. This result was obtained through a randomized, double-blind, placebo-controlled multi-centre trial investigating the potential benefit of supplementing the flu shot in seniors with COLD-FX, the Company's lead product and Canada's number one selling cold and flu remedy.

Read at Market Wired


comments powered by Disqus
   
Influenza

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES